2021-01-04,"b'Stocks with expensive options (high IV/IV percentile)  watch-list for Jan 04, 2021 $QQQ $SPY $IWM #success #trading #options #stock\n$GSX $SFIX $EDIT $BNTX $SRPT $PDD $STMP https://t.co/5atcDjFvh5'"
2021-01-04,"b'RT @Sports_bios: Obviously, w/ virtual JPM confer looming, people have their own list of interest.. for me, however little time I have to s\xe2\x80\xa6'"
2021-01-04,"b""Obviously, w/ virtual JPM confer looming, people have their own list of interest.. for me, however little time I have to spare these days, am thinking about how big and important the readout of $SRPT Gtx on DMD be - it's kinda like the binary readout of the 36/48 wk Etep 6mW."""
2021-01-04,b'RT @AuricGoldFinqer: $SRPT Sarepta price target raised to $240 from $200 at Piper Sandler. https://t.co/00MAe0HI1I'
2021-01-04,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-04,b'$SRPT Sarepta price target raised to $240 from $200 at Piper Sandler. https://t.co/00MAe0HI1I'
2021-01-04,b'RT @BioStocks: $SRPT PT raised to $240 at Piper'
2021-01-04,b'Next Monday $SRPT will be'
2021-01-04,b'@lblegend33 @LTbioinvestor $SRPT this week? Prior to G Tx data drop?'
2021-01-04,b'RT @BioStocks: $SRPT PT raised to $240 at Piper'
2021-01-04,b'RT @BioStocks: $SRPT PT raised to $240 at Piper'
2021-01-04,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 187'
2021-01-04,b'$SRPT PT raised to $240 at Piper'
2021-01-04,b'RT @_B_I_O_T_E_C_H_: PIPER $SRPT Increasing PT To $240 To Reflect SRP-9001/Microdystrophin Study 102 Success \n$RCKT Increasing PT To $80 To\xe2\x80\xa6'
2021-01-04,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-04,"b""RT @OxAnalyst: Estimated movement for $XBI January binary events:\n\n$AMGN $BMRN $CRDF $MRSN $SRPT $VIR\n\nGuided for 'early Q1-2021' but not i\xe2\x80\xa6"""
2021-01-04,b'RT @_B_I_O_T_E_C_H_: PIPER $SRPT Increasing PT To $240 To Reflect SRP-9001/Microdystrophin Study 102 Success \n$RCKT Increasing PT To $80 To\xe2\x80\xa6'
2021-01-04,b'RT @_B_I_O_T_E_C_H_: PIPER $SRPT Increasing PT To $240 To Reflect SRP-9001/Microdystrophin Study 102 Success \n$RCKT Increasing PT To $80 To\xe2\x80\xa6'
2021-01-04,b'PIPER $SRPT Increasing PT To $240 To Reflect SRP-9001/Microdystrophin Study 102 Success \n$RCKT Increasing PT To $80 To More Appropriately Reflect The Danon Opportunity'
2021-01-04,b'Sarepta price target raised to $240 from $200 at Piper Sandler\n$SRPT'
2021-01-04,"b""RT @OxAnalyst: Estimated movement for $XBI January binary events:\n\n$AMGN $BMRN $CRDF $MRSN $SRPT $VIR\n\nGuided for 'early Q1-2021' but not i\xe2\x80\xa6"""
2021-01-04,"b""Estimated movement for $XBI January binary events:\n\n$AMGN $BMRN $CRDF $MRSN $SRPT $VIR\n\nGuided for 'early Q1-2021' but not included:\n$CALA Ph2 RCC\n$KALV Ph2 HAE\n$NVAX Ph3 COVID (UK data) https://t.co/2n7xTMGbMZ"""
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,"b""RT @biostonks: I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the\xe2\x80\xa6"""
2021-01-04,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-04,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-04,"b'Six down days in a row, hoping for a $Srpt Green Day tomorrow'"
2021-01-04,b'RT @GreyZone5l3: $SRPT This video is a great reminder of what is likely coming soon from Sarepta. https://t.co/v4KkniotrG'
2021-01-04,b'$SRPT\n\nVery interested in this name for my long term holds.\n\n- Breaking out of 20-yr base and ATH \n- Multi-month inverted head and shoulder https://t.co/7latI3pfdz'
2021-01-04,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-04,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-04,"b'$SRPT\n\nAs a reminder, for hitting milestones Sarepta is eligible to receive another $1.7 billion from Roche.  I would guess the upcoming trial results qualify as a milestone. What would that mean for the market cap?'"
2021-01-04,b'Last year $XBI. $SRPT $FOLD $NBIX $ALNY $GWPH $CLVS all preannounced early jan last year ???'
2021-01-04,b'$SRPT $170.49 -1.05  -0.61%SRP-9001 - Study 102\nDuchenne muscular dystrophy Phase 2 data due 1Q 2021. Study 103 to commence later in 2020.\n$CHRS $17.38 -0.19  -1.08%CHS-1420 PsoriasisBLA \nBLA filing due 1Q 2021.'
2021-01-03,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-03,"b'$ABBV $107.15 +1.88  +1.79% Botox Neurogenic Netrusor Overactivity PDUFA 1Q 2021 sBLA filing accepted June 22, 2020. PDUFA date 1Q 2021.\n$SRPT $170.49 -1.05  -0.61%Casimersen Duchenne muscular dystrophy PDUFA priority review 02/25/2021\nPDUFA date under priority review'"
2021-01-03,b'RT @Zen_Options: Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TD\xe2\x80\xa6'
2021-01-03,b'Couldn\xe2\x80\x99t narrow my 2021 list down so here is a longer list of \xe2\x80\x98some\xe2\x80\x99 of the many names I\xe2\x80\x99ll have an eye on this year:\n\n$TDOC\n$SKLZ\n$GS\n$AMKR\n$FB\n$PINS\n$SRPT\n$GMED\n$PGNY\n$JMIA\n$MU\n$SYNA\n$NNOX\n$BB\n$ZI\n$CURI\n$TWTR\n$AMZN\n$SE\n$DOCU\n$ARKG (and underlying companies)\n$HAACU\n$CMLF\n$FUTU'
2021-01-03,b'$SRPT https://t.co/OSwq8iEOwl Sarepta Therapeutics Inc The artificial intelligence foresees the value of this company won t see its price moving much shortly and has weak long term fundamentals #investing #motivation #credit'
2021-01-03,"b'@R_W_009 @Bionerd51 @RBBio1 @Hall8Jack @TomSilver39 $srpt Law explicitly allows for smaller and fewer trials for rare/unmet  diseases. Note that \xe2\x80\x94 in Etep saga, NOT EVEN ONCE did FDA bring up the small trial size (12) as a negative.'"
2021-01-03,"b'Does 80-90% reduction in CK values mean too much (ie, are they much convincing in terms of clinical benefit)? $srpt FDA doesn\xe2\x80\x99t regard reduction in CK as a valid surrogate marker. https://t.co/CQKQAQBRvy'"
2021-01-03,b'RT @GreyZone5l3: $SRPT This video is a great reminder of what is likely coming soon from Sarepta. https://t.co/v4KkniotrG'
2021-01-03,b'RT @GreyZone5l3: $SRPT This video is a great reminder of what is likely coming soon from Sarepta. https://t.co/v4KkniotrG'
2021-01-03,b'$SRPT This video is a great reminder of what is likely coming soon from Sarepta. https://t.co/v4KkniotrG'
2021-01-03,"b""I've created an Excel spreadsheet that will self-update the market cap movement of 74 gene therapy players and will post the changes at the end of each week in 21'. $VRTX $SRPT $EXAS $CRSP $RARE $ARWR $BBIO $RCKT $EDIT $BLUE $SGMO $QURE $RGNX $FLGT $ZIOP $VYGR $SIOX $ABEO https://t.co/I0ROS0RjAq"""
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,"b""@GreyZone5l3 Thanks. Those videos available anywhere? Can't find them anywhere ... $SRPT"""
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'RT @sssvenky: My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTO\xe2\x80\xa6'
2021-01-03,b'My Top picks starts with names in the following ETFs: \n\n$CIBR - $ZS $CRWD $SPLK\n$HACK - $FEYE $SPLK $OKTA \n$IBUY - $ETSY $PTON $UBER\n$ARKW $CLOU - $NET $TWLO $TTD\n$TAN - $SEDG $ENPH\n$IBB $ARKG - $SRPT $HZNP\n\n#VenkyTopPicks2021 #EducationalPurposeOnly #Part1'
2021-01-02,"b'@Bionerd51 @Hall8Jack @TomSilver39 $srpt is not trying for AA, because the relationship of uD to clinical benefit is not known and thus AA can\xe2\x80\x99t be granted, unless the trial shows the correlation \xe2\x80\x94 in which case, there is almost no diff between full approval and AA. AA is not \xe2\x80\x9cconditional\xe2\x80\x9d approval.'"
2021-01-02,b'$srpt What data/evidence gives you the most confidence that uD expression implies clinical benefit (improvement in NSAA scores)? Ignore the age-group. I\xe2\x80\x99m trying to judge the prob of success of the uD trial. I\xe2\x80\x99m very confident that uD exp will happen; not so sure about NSAA imp.'
2021-01-02,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-02,"b'Besides having an excellent technical rating, $SRPT also presents a decent setup pattern. https://t.co/wUpaI6qc7g https://t.co/F9mtM3bEC1'"
2021-01-02,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-02,"b""RT @kylewdennis: I played the $SRPT data dip in the after hours. Never deserved to be down to $130's on fantastic data. +$11,890! What a wa\xe2\x80\xa6"""
2021-01-02,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-01,b'1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Melanoma ph3\n$NVS Iptacopan(Factor B) IgAN ph2\n$SRPT SRP-9001 DMD ph2\n$SNDX-5613 MLL-r/NPM1 AML ph1\n\nCovid-19 Vaccine:\n$AZN US ph3\n$JNJ US ph3\n$NVAX UK ph3 https://t.co/GvakdEQgNI'
2021-01-01,"b'Popular: $RWT, $NVS, $CWH, $NXPI, $BNB.X, $SRPT, $RTX, $BCH.X, $AERI, $SVXY, $PGEN, $SCS, $CEO'"
2021-01-01,b'@srqstockpicker $arkg already owns $vrtx $srpt $crsp $edit $ntla $beam etc but if Vertex or Sarepta start #CRISPR DMD trial I would expect CW to load up on vrtx/srpt in her $arkk fund also. We\xe2\x80\x99ve already seen the effect ARKK can have on crazy multiples....'
2021-01-01,b'Should I Go Long or Short $SRPT ?'
2021-01-01,b'@srqstockpicker $srpt / Gersbach contd https://t.co/IxYH8HjRez'
2021-01-01,b'@srqstockpicker Don\xe2\x80\x99t give up on $SRPT / Gersbach-Duke either #DMD #CRISPR https://t.co/y8VMo8MtNH'
2021-01-01,b'LOL at these absurd $SRPT narratives. https://t.co/hzpcs0EWfX'
2021-01-01,b'Short sale vol (not short interest) for $BCRX on 2020-12-31 is 40%. https://t.co/vE0yL3qZm0 $XLV 60% $SRPT 50% $AVIR 63% $NNVC 38%'
2021-01-01,b'@Bionerd51 @RBBio1 @Hall8Jack @TomSilver39 $SRPT\n\nAveXis/Novartis had their SMA gene therapy approved with small trials that combined only had 36 patients.'
2021-01-01,b'RT @Bionerd51: @RBBio1 @Hall8Jack @TomSilver39 $SRPT For the record I am a very long term large shareholder. Why would the FDA accept an ND\xe2\x80\xa6'
2021-01-01,"b""@RBBio1 @Hall8Jack @TomSilver39 $SRPT For the record I am a very long term large shareholder. Why would the FDA accept an NDA filing for microdsytrophin [N=40] GT when there are only a couple of boys treated with 9001 in some of the rarer exons in this cohort of Tx'ed patients?"""
2021-01-01,"b'RT @Bionerd51: @GreyZone5l3 @Hall8Jack @TomSilver39 $SRPT Ingram significantly increased the Phase III ""N"" because of the difficulty of dem\xe2\x80\xa6'"
2021-01-01,"b'@GreyZone5l3 @Hall8Jack @TomSilver39 $SRPT Ingram significantly increased the Phase III ""N"" because of the difficulty of demonstrating clinical significant outcomes over 2 years Vs. placebo. We are no longer in the land of historical cohorts.'"
2021-01-01,b'$rhhby 1.19% \xf0\x9f\x91\x80\n$rptx 1.74% \xf0\x9f\x91\x80\n$sdgr -0.24%\n$srpt -0.24%\n$surf -0.24%\n$syrs -0.24%\n$tak un -0.24%\n$tdoc 4.01% \xf0\x9f\x91\x80\n$tmo -0.24%\n$twst -0.24%\n$txg -0.24%\n$vcyt -0.24%\n$veev -0.24%\n$vrtx -0.24%'
2020-12-31,b'$SRPT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nasdaq:SRPT https://t.co/o1nEeuZAie'
2020-12-31,b'$SRPT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://t.co/NxRM3Be9kD'
2020-12-31,b'$SRPT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\nFrom our Stock News Alerts App'
2020-12-31,"b'$SRPT #NASDAQ News: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [B/A=0/0 - Bid/Ask Size=0/0  Volume=720,716  AverageVol=692,580  Outstanding=0] https://t.co/ee3yfsrLs7'"
2020-12-31,b'Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 $SRPT https://t.co/J7gPQDVRyA'
2020-12-31,b'$SRPT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\nhttps://t.co/j7gMQGE1cr'
2020-12-31,"b'@valeantadvisors @DavidSchawel $SRPT December 30, 2011 Sarepta closed at $4.47 (split adjusted). Today, nine years later, Sarepta closed at $170.49.'"
2020-12-31,b'@DavidSchawel Now do Sarepta Therapeutics Inc $SRPT'
2020-12-31,"b'$SRPT\nOf course, today is the end of 13F holding period/reporting period; perhaps some window dressing into the close.  Also SI reporting period closes today, report out after close on 1/11 (JPM start day).'"
2020-12-31,b'@MSollender $SRPT probably the biggest catalyst mover in terms of market cap'
2020-12-31,b'2021 is the year of clinical success and M&amp;A with many potential companies\nTo mention some of my candidates\n$SRPT the next $VRTX\n$APTO  next $ARQL\n$CRTPF next $GWPH\n$PINK.v $PYNKF SoC #BreastCancer imaging\n$APLIF $APLI Canadian EUA\n$MDNA Partnering &amp; IL-2\n$XAIR $BLU &amp; many more'
2020-12-31,b'RT @BioStocks: $SRPT readout from Phase 2 microdystrophin gene therapy trial potentially could be the biggest biotech binary event of year\xe2\x80\xa6'
2020-12-31,"b'RT @TomSilver39: RJ:"" $SRPT Kick Starting 2021 With SRP-9001 Data: Outcomes: (1) stat sig and clinically sig, stock to $230-$240; (2) stat\xe2\x80\xa6'"
2020-12-31,"b'@Hall8Jack @TomSilver39 $SRPT Statistical significance is not the barometer. The clinical improvement Vs. placebo cohort has to be a ""home run"" for the FDA to allow SRPT to file for AA with a 40 patient cohort. Truncated protein and multiple exons weighs against AA'"
2020-12-31,"b""@Hall8Jack $SRPT SRP-9001's over placebo needs to be \xe2\x89\xa53 points (ideally 4+) to be viewed as clinically significant."""
2020-12-31,b'@TomSilver39 What would be an example of statistically significant but not clinically sig? $srpt'
2020-12-31,"b'RT @TomSilver39: RJ:"" $SRPT Kick Starting 2021 With SRP-9001 Data: Outcomes: (1) stat sig and clinically sig, stock to $230-$240; (2) stat\xe2\x80\xa6'"
2020-12-31,"b""@TomSilver39 Well we already know it won't be outright fail, so I'm guessing #1 @ 75% and #2 @ 20%, #3 @ 5% $SRPT"""
2020-12-31,"b'RJ:"" $SRPT Kick Starting 2021 With SRP-9001 Data: Outcomes: (1) stat sig and clinically sig, stock to $230-$240; (2) stat sig but not clinically sig, stock to ~$210; (3) not stat sig, but strong efficacy trends, stock to $105-$120 and; (4) outright failure, stock to ~$60....""'"
2020-12-31,"b'RT @Quantumup1: Raymond James~ $SRPT data could be biggest biotech binary event of year, thinks trial will show a statistically significant\xe2\x80\xa6'"
2020-12-31,b'Oversold on Hourly  \rhttps://t.co/2Hf0ZbjpKC \r$XRT  65.20  to 64.25 \r$YUMC  57.50  to 56.82 \r$JKS  67.52  to 61.25 \r$SRPT  174.35  to 168.03 \r$TNDM  96.67  to 95.02 \r$BAH  87.70  to 86.26 \r$BIG  44.82  to 42.73 \r$DG  211.60'
2020-12-31,"b'Last infusion for 2020, #488 is in the books with zero AE\xe2\x80\x99s. Still walking in each week, next infusion he will be 20 years old. #eteplirsenpioneer #Duchenne $SRPT #exondys51 https://t.co/aEmEvTpa32'"
2020-12-31,b'RT @GantosJ: @dmshetayh @abbynac @BioStocks $SRPT said Study-102 data in 1Q-2021\nBut as we know last patient last visit was 12/14 so SRPT i\xe2\x80\xa6'
2020-12-31,b'@dmshetayh @abbynac @BioStocks $SRPT said Study-102 data in 1Q-2021\nBut as we know last patient last visit was 12/14 so SRPT is already working on the data analysis &amp; might be out any day in Jan to max mid Feb IMHO\n\nI would love to see the data at JPM big event :-))'
2020-12-31,"b""No I did not sell at $181...I've waited this long. I can wait longer. $SRPT Q1 should be a beautiful thing."""
2020-12-31,b'RT @BioStocks: $SRPT readout from Phase 2 microdystrophin gene therapy trial potentially could be the biggest biotech binary event of year\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $SRPT readout from Phase 2 microdystrophin gene therapy trial potentially could be the biggest biotech binary event of year\xe2\x80\xa6'
2020-12-31,b'RT @BioStocks: $SRPT readout from Phase 2 microdystrophin gene therapy trial potentially could be the biggest biotech binary event of year\xe2\x80\xa6'
2020-12-31,b'$SRPT readout from Phase 2 microdystrophin gene therapy trial potentially could be the biggest biotech binary event of year - Raymond James'
2020-12-31,b'RT @NicoSEnea: @Hedgeye Keith is a a little bitch that doesn\xe2\x80\x99t even sail in 2008 he was scratching around trying to get on media outlets. H\xe2\x80\xa6'
2020-12-31,b'$srpt reiterates $200 pt at Raymond James'
2020-12-31,b'@Hedgeye Keith is a a little bitch that doesn\xe2\x80\x99t even sail in 2008 he was scratching around trying to get on media outlets. He blocked me back in the day b/c he told a little biotech $SRPT was going to zero and we got into a twtr spat.. it went from $35 to $171 good call ya Bish'
2020-12-31,"b'$SRPT Raymond James has $200 target but calls January data ""the biggest binary event of the year""; effectively, SRPT needs robust data to reach target and the bar is high given valuation'"
2020-12-31,"b""Raymond James~ $SRPT data could be biggest biotech binary event of year, thinks trial will show a statistically significant improvement on the study's primary NSAA endpoint, says SRP-9001's delta over placebo needs to be &gt; than or = to 3 points, or ideally 4+\n\nOutperform~$200 PT"""
2020-12-31,"b'$SRPT (+0.0% pre) Sarepta Therapeutics (SRPT) Could Move 40% in the Next 30 Days on This Binary Event, Raymond James Reiterates Outperform\n\nhttps://t.co/UTSpACTqkI'"
2020-12-31,"b""RT @sbwcws: Sarepta data 'could be biggest biotech binary event of year,' says Raymond James\n$SRPT"""
2020-12-31,"b""Sarepta data 'could be biggest biotech binary event of year,' says Raymond James\n$SRPT"""
2020-12-31,"b""Raymond James maintained $SRPT coverage with Outperform and target $200\nI think it's a lot more. I'm long $SRPT"""
2020-12-31,"b'Stocks with expensive options (high IV/IV percentile)  watch-list for  Dec 31, 2020 $QQQ $SPY $IWM #success #trading #options #stock\n$SFIX $EDIT $JD $SRPT $PDD $STMP $BABA https://t.co/gL1sPyUWTP'"
2020-12-31,"b'$sdgr 2.94%\n$srpt 2.94%\n$surf 2.94%\n$syrs 0.00%\n$tak un 4.88%\n$tdoc 2.94%\n$tmo 2.94%\n$twst 2.94%\n$txg 2.95%\n$vcyt 0.00%\n$veev 2.94%\n$vrtx 2.94%\n\nnote: $aqb was ""frozen"" today and did not get a portion of the etf inflows'"
2020-12-30,b'@fedupbizowner @RetirementRight I just hope they wait until after the $SRPT data drops around then.'
2020-12-30,b'Stock and Options trading system. VolatilityTrader: https://t.co/eVwKMfovby $SVXY $W $WYNN $UVXY $SRPT $TIF $TGT $LOW $TWLO $VIX $FN $MON'
2020-12-30,b'RT @MarcJacksonLA: $BIIB $SRPT $JNJ $GSK $SNY $NVAX Biotech Stocks Ready for More Covid-19 Results in First Quarter https://t.co/crAvqIcqCW'
2020-12-30,b'$XBI\n$SRPT\n$FOLD\n$NBIX\n$ALNY\n$GWPH\n$CLVS\n$ADMS https://t.co/XMRXKbW2DL'
2020-12-30,b'Auto-trading subcriptions available at Profectus Systems: $REXX $WLL $SRPT $GALE $XOM $F $GM $NKE $SBUX $FCX $LUV $AAL $PZZA $DPZ'
2020-12-30,b'Me watching $SRPT and $TRIL today https://t.co/J3suVWeD1w'
2020-12-30,"b""Rose Above Previous Day's High today: $SRPT $SIVR $LE $DBC $ARVN $EIGR $KLAC $DALT $ICUI $COLM $UHS $AVNS $LRN $CIVB $FLY $PRGO $TRS $MDT $BHC $DHI ... https://t.co/TBYRpvrFqi"""
2020-12-30,b'$BIIB $SRPT $JNJ $GSK $SNY $NVAX Biotech Stocks Ready for More Covid-19 Results in First Quarter https://t.co/crAvqIcqCW'
2020-12-30,b'$SRPT - keep an eye on this one...can breakout any time https://t.co/frki0Wxkq0'
2020-12-30,b'$SLDB is a stock I want in my portfolio next year. \nIt passed my endurance test.\nAnother DMD player like $SRPT and $PTCT'
2020-12-30,"b""The only stock I'm holding for over 4 years and haven't sold even 1 share is $SRPT that I bought back in July 2016 for $19.85 \nI'm still looking for the price to start trading in the $200's, might sell 50% around $250 and the rest over $300\nThanks Joe for the best pick ever,"""
2020-12-30,b'$SRPT will see you at $300 $BMRN $QURE $CLVS other majored takeover targets right after Sarepta !'
2020-12-30,b'@Zen_Options Ha! I was wondering where I heard about $SRPT.  Looking good today~'
2020-12-30,b'$SRPT \nback above 175 key level\nStill much potential'
2020-12-30,"b'Stocks with expensive options (high IV/IV percentile)  watch-list for Dec 30, 2020 $QQQ $SPY $IWM #success #trading #options #stock\n$SFIX $EDIT $JD $PDD $SRPT $STMP $BABA https://t.co/RWyjlY9vHr'"
2020-12-30,b'$CAPR 11/n haven\xe2\x80\x99t confirmed the content but the dmd opportunity is just staggering compared to current mkt cap of under $80M. Look where $SRPT trades. \n\nPs: stole the graphic from this dude https://t.co/17buIYSHTx https://t.co/26QTX6Rn3v'
2020-12-30,b'$SRPT Was up 1.21 %. Turned negative -1.34% | (Green to red move) #GreenToRed https://t.co/GVxlCwgmt1 https://t.co/ndlhMIvtEL'
2020-12-29,b'@given2tweet Not that issue.  Is there an undisclosed deficiency on BMY\xe2\x80\x99s side.  I am thinking $srpt redux where it is not just a matter of inspection'
2020-12-29,b'$SRPT - Sarepta Therapeutics rated outperform by Baird on positive biomarker data https://t.co/FuMbKIZNF7'
2020-12-29,b'2020-12-28 Short sale volume (not short interest) for $CPRX is 55%. https://t.co/98fO0eTJ77 $SRPT 44% $PFE 32% $XLV 74%'
2020-12-29,"b'@SunriseTrader Almost got sideways, FOMO, on $AMZN again, then realized I can make just as much or more on $SRPT.  Trade your plan or as I say, Stay the Course.'"
2020-12-29,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 322'
2020-12-29,b'$SRPT $LYSGF - Sarepta Therapeutics rated outperform by Baird on topline biomarker data https://t.co/RbaVl76YTL'
2020-12-29,b'@srqstockpicker Same my friend! $TRIL $TCON $ONCT $CRIS $SRPT $GME and your favorite $SGMO here.'
2020-12-29,b'Can add:\n\n$SE\n$SRPT'
2020-12-29,"b'REVERSALtoDOWN: $SRPT Sarepta Therapeutics, Inc https://t.co/Gc789PQM2U \xf0\x9f\x93\x89 \xf0\x9f\x94\x9c TradeIdeas via \xe2\x9f\xb6 https://t.co/ZgCyz4rX3x'"
2020-12-29,"b'$SRPT Morgan missing the point that SRPT has already  become highly desirable acquisition target ! The pipeline is broad, investments made will pay off, this is a $300 stock. Idiots are buying pumped up nonsense like $TENX an... https://t.co/x2RA01hRIS'"
2020-12-29,"b""RT @Quantumup1: $SRPT\nAnalyst Commentary\nMorgan Stanley's expectations are high on SRP-9001, given the durability reported in the prior stu\xe2\x80\xa6"""
2020-12-29,b'@AREM325 $SRPT upcoming Sarepta milestones including SRP-9001 trial 102 data readout. https://t.co/dBQ6AfCoK4'
2020-12-29,"b'Stocks with expensive options (high IV/IV percentile)  watch-list for Dec 29, 2020 $QQQ $SPY $IWM #success #trading #options #stock\n$SFIX $JD $EDIT $AMBA $PDD $CRSP $SRPT $STMP $BABA $AMZN https://t.co/oRjRe6lWIY'"
2020-12-29,"b'$SRPT MS maintains Overweight, PT 182'"
2020-12-29,"b""RT @Quantumup1: $SRPT\nAnalyst Commentary\nMorgan Stanley's expectations are high on SRP-9001, given the durability reported in the prior stu\xe2\x80\xa6"""
2020-12-29,"b""$SRPT\nAnalyst Commentary\nMorgan Stanley's expectations are high on SRP-9001, given the durability reported in the prior study of the gene therapy\n\nOverweight rating~$182 PT https://t.co/Y1lMm8pMNC"""
2020-12-29,"b'Sarepta has upcoming catalyst in SRP-9001 study readout, says Morgan Stanley\n$SRPT'"
2020-12-29,b'#ARK_M50 (1)\n$IONS +108.3\n$RHHBY +100\n$GOOGL +100\n$OPEN +100\n$VEEV +100\n$PTON +100\n$CRM +100\n$SRPT +100\n$MASS +100\n$4477 +100\n$MGA +100\n$KSPI +100\n$6618 +100\n$NXPI +97.1\n$CDXS +95\n$9923 +92.7'
2020-12-29,b'Auto-trading subcriptions available at Profectus Systems: $REXX $WLL $SRPT $GALE $XOM $F $GM $NKE $SBUX $FCX $LUV $AAL $PZZA $DPZ'
2020-12-29,"b'$SRPT Sarepta Therapeutics, Inc Top stock up 117% from low. Close: 174.15 VolvsAvg: 0.57 Liq: $85M https://t.co/TtgntF6MMG'"
2020-12-29,"b'RT @AREM325: Hmm.. $SRPT wonder if the massive juice in options is all for the study 102 due ""very early"" 2021'"
2020-12-29,"b'Hmm.. $SRPT wonder if the massive juice in options is all for the study 102 due ""very early"" 2021'"
2020-12-29,b'@Brady_Atlas Add two other gene therapy names to your list. $SRPT and $QURE'
2020-12-28,b'$SRPT\n\nPositive news from the MPSIII gene therapy partnership between Sarepta and Lysogene.\n\nhttps://t.co/HWA2zu2qSk'
2020-12-28,"b""Rose Above Previous Day's High today: $BLE $DGRW $FNDB $GIGM $HQI $EMIF $AAME $PLAT $ESGR $GRIF $DUSL $RNLX $SNES $AIRI $PNRG $SRPT $DRQ $UMH $OLP $ARR ... https://t.co/TBYRpvrFqi"""
2020-12-28,b'$SRPT [Dec-24 170 Calls] up +152.73%  Alerted at $4.40  on Dec 17 2020  1:21PM Peak after alert $11.12 on 2020-12-23  \n\rDaily Progress: https://t.co/I7O6syF9pj https://t.co/zXhLeKsCwW'
2020-12-28,b'$SRPT [Dec-24 175 Calls] up +102.70%  Alerted at $3.70  on Dec 18 2020 10:20AM Peak after alert $7.50 on 2020-12-22  \n\rDaily Progress: https://t.co/CIy51AqUwg https://t.co/6grXc0OekS'
2020-12-28,b'Peak profit for the last 6 expired option alerts for $SRPT 432.79% | 418.91% | -81.22% | -22.41% | 2.69% | 4.17% |   \n\rhttps://t.co/GhXbXhi3mE https://t.co/kD3kfgE28s'
2020-12-28,b'$SRPT - #OptionsTrading - Monthly performance of the algo based option alerts posted for SRPT \n\rhttps://t.co/zVrtF59eoH'
2020-12-28,"b'$SRPT - Last six months, 14 option alerts peaked above 100% after they were triggered by the algo  \n\rhttps://t.co/GhXbXhi3mE https://t.co/xFnz09xY96'"
2020-12-28,b'$srpt showing a little relative strength here'
2020-12-28,b'$SRPT\nComing off support.\nVery good risk/reward vs. today\xe2\x80\x99s low\nThe name still has massive breakout potential.'
2020-12-28,b'RT @Pharmdca: @autrader1 @JonahLupton @GrowthStockGuru @Soumyazen @TheMarkCooke @saxena_puru @tribefankyle @LuoshengPeng @JoeySolitro @Terr\xe2\x80\xa6'
2020-12-28,b'RT @Pharmdca: @autrader1 @JonahLupton @GrowthStockGuru @Soumyazen @TheMarkCooke @saxena_puru @tribefankyle @LuoshengPeng @JoeySolitro @Terr\xe2\x80\xa6'
2020-12-28,"b'$goog $fb $msft $nflx $qqq $amzn $bbry $yhoo $srpt $intc $wag $jcp $gs $bac $o $jpm $s $hlf $ibm $lxrx $aapl $snts $hp $crm $vmw $dell $orcl $attu $rax $wday $tsla $ebay $gold $sbux $trip $qcom $znga $fslr $intc $srpt\n\xe2\x80\x94-\n\n\xe2\x9a\xa0\xef\xb8\x8f Price up 10,000% this year! \xe2\x9a\xa0\xef\xb8\x8f \n\nJust getting started? https://t.co/cy8NK72RJs'"
2020-12-28,"b'Stocks with expensive options (high IV/IV percentile)  watch-list for Dec 28, 2020 $QQQ $SPY $IWM #success #trading #options #stock\n$SFIX $EDIT $PDD $CRSP $SRPT $STMP $BABA https://t.co/UK65SXEB6T'"
2020-12-28,b'RT @Tijori1: Gene editing companies listed in the US\n\nBluebird Bio $BLUE\nCrispr Therapeutics $CRSP\nEditas Medicine $EDIT\nIntellia Therapeut\xe2\x80\xa6'
2020-12-28,b'RT @Tijori1: Gene editing companies listed in the US\n\nBluebird Bio $BLUE\nCrispr Therapeutics $CRSP\nEditas Medicine $EDIT\nIntellia Therapeut\xe2\x80\xa6'
2020-12-28,"b'really help us much for now vs a potential hit on primary endpoint. These HS in CSF numbers will be out for sure mid-February for $LYS $SRPT LBA presentation at WorldSymposium 2021. (Abeona also has an update of ABO-102 Transpher A at the same event), so hopefully more clarity'"
2020-12-27,b'RT @Pharmdca: @autrader1 @JonahLupton @GrowthStockGuru @Soumyazen @TheMarkCooke @saxena_puru @tribefankyle @LuoshengPeng @JoeySolitro @Terr\xe2\x80\xa6'
2020-12-27,b'2020-12-24 Short sale volume (not short interest) for $BCRX is 36%. https://t.co/vE0yL3qZm0 $AVIR 54% $XLV 56% $NNVC 55% $SRPT 36%'
2020-12-27,b'RT @Pharmdca: @autrader1 @JonahLupton @GrowthStockGuru @Soumyazen @TheMarkCooke @saxena_puru @tribefankyle @LuoshengPeng @JoeySolitro @Terr\xe2\x80\xa6'
2020-12-27,"b'@autrader1 @JonahLupton @GrowthStockGuru @Soumyazen @TheMarkCooke @saxena_puru @tribefankyle @LuoshengPeng @JoeySolitro @TerraPharma1 $PSNL Investment thesis: Recent launch of Liquid Biopsy test, company\xe2\x80\x99s analysis of 20,000 plus gene pool compared to $GH of only 500 plus, Big expansion in China, Expansion outside of Oncology including $SRPT, One stop for Research and Clinical use vs going through diff. vendors'"
2020-12-27,b'PDUFA LIST FOR\n\n$OSMT $MRK $AUPH $PFE $AMGN\n$ADMS $MNK $REGN $TGTX $GTHX\n$EXEL $BMY $SRPT $REGN $SNY \n$CRMD $BPMC $ATNX\n\n#Business #PennyStocks\n#Stocks #Daytrader #Finance https://t.co/kDob3UoHIr'
2021-01-08,b'$SRPT wow. No amount of DD will ever reveal drug trial results.'
2021-01-08,"b'$SRPT , $BTC , Trump, $ARGX &amp; $JNJ right there at the back. \nAnything else today? \nAlready muting crypto fans until they get clonazepam IV #CalmDown'"
2021-01-08,b'@biotechinvstr Why does $SRPT get away with running 2-center trials in the first place?'
2021-01-08,b'Worst performing large cap stocks so far today\n\nSarepta $SRPT\nOpendoor $OPEN\nQuantumScape $QS\nSirius XM $SIRI\nSibanye $SBSW\nKinross $KGC\nWheaton $WPM\nAgnico $AEM\n$UBER\nKirkland $KL\nBarrick $GOLD\nWestern Digital $WDC\nLiberty $LSXMA\nAT&amp;T $T\n$WISH\nArcelor $MT\nAngloGold $AU\n$CS'
2021-01-08,"b'Come to poppa, $srpt'"
2021-01-08,b'@MauriceOnTW @Sports_bios $RGNX just announced their own preclinical #DMD candidate this week. This $SRPT data gives them the added luxury of information going forward.'
2021-01-08,b'$SRPT = risky = but why not = half off = let see if it move a bit after-hour or next week ! small profit is better then nothing if happen\nhttps://t.co/CHabSnZaeY'
2021-01-08,b'RT @StockMKTNewz: Worst performing large cap stocks so far today\n\nSarepta $SRPT\nOpendoor $OPEN\nQuantumScape $QS\nSirius XM $SIRI\nSibanye $SB\xe2\x80\xa6'
2021-01-08,"b""$SRPT Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock https://t.co/8uOhpo7sjN"""
2021-01-08,b'Most active options Friday - $AAPL $TSLA $NIO $QS $BABA $PLTR $PLUG $AMD $MU $AMZN $IDEX $FB $BAC $DKNG $T $BIDU $SQ $FCEL $MARA $AAL $BA $MSFT $SNOW $RIOT $TLRY $LI $AMC $UBER $ROKU $CVS $SNDL $CCL $CRM $SNAP $X $C $VALE $F $ETSY $TWTR $M $NVDA $TSM $SRPT $TEVA $ACB $IPOE $BB https://t.co/RAt3NbSSOo'
2021-01-08,b'Worst performing large cap stocks so far today\n\nSarepta $SRPT\nOpendoor $OPEN\nQuantumScape $QS\nSirius XM $SIRI\nSibanye $SBSW\nKinross $KGC\nWheaton $WPM\nAgnico $AEM\n$UBER\nKirkland $KL\nBarrick $GOLD\nWestern Digital $WDC\nLiberty $LSXMA\nAT&amp;T $T\n$WISH\nArcelor $MT\nAngloGold $AU\n$CS'
2021-01-08,"b'$SRPT stock trading volume up by +645.04% | 7,828,764 vs 1,050,779 \n\r https://t.co/mTl9ztTRaZ'"
2021-01-08,"b""RT @GebittMetrics: HIRING ANALYSIS\xf0\x9f\xa7\x91\xe2\x80\x8d\xf0\x9f\x8c\xbe\nHiring activity plunged by roughly 50% during the month before today's results from the drug study.\n#\xe2\x80\xa6"""
2021-01-08,"b""@Sports_bios A lot of ?'s for $SLDB $PFE $SRPT RGNX ... to digest here would like to see peoples thoughts not just tweets gloating\n\n1. Is Fn of micro-d &lt;&lt; Dystrophin?\n2. Why micro-d levels much lower than 101?\n3. How much diff did baseline play?\n4. Diff transgenes perform diff on NSAA?\n..."""
2021-01-08,"b""$SRPT is why I can't swing $PFE $GILD $MRNA.  Investors had ZERO chance to get out.. just like what happened to $QS last week.  50% loss overnight.   $TSLA happy now, but wait for your turn. https://t.co/DkQblr8tCq"""
2021-01-08,b'RT @adamfeuerstein: To follow up on an observation made earlier by @zbiotech:\n\n$CRSP market cap $14B \n\n$SRPT market cap $6.5B \n\nThe lesson:\xe2\x80\xa6'
2021-01-08,"b'Hat-tip to @JacobPlieth for pointint out $SRPT ""defense based on claim that cohorts had imbalanced baseline characteristics \xe2\x80\x93 despite earlier playing up how well balanced the trial was at investor conferences."" - https://t.co/nyEDHERYuE'"
2021-01-08,"b""RT @JacobPlieth: The market doesn't buy $SRPT 's excuses. Quick take on Study 102 via @evaluatevantage https://t.co/T9soZA3K9p $PFE $SLDB"""
2021-01-08,b'$SRPT the risks of Bio-Pharma! Make sure you do DD https://t.co/BXcD6K6q0k'
2021-01-08,b'$SRPT 15-Jan-21 ATM Implied Vol Decreases -47.3% to 112.3. Straddle Implies a Move of \xc2\xb113.2% https://t.co/zSEXcX5CZu'
2021-01-08,"b'$SRPT Leerink Maintains Buy Rating On Sarepta Therapeutics, $125 PT https://t.co/8i9qXcfYqe'"
2021-01-08,b'$SRPT has investors not feeling well today on disappointing clinical data $SLDB https://t.co/VMkDTJTFNS'
2021-01-08,b'Big Loser Alert: Trading today\xe2\x80\x99s -48.6% move in SAREPTA THERAPEUTICS INC. COM\xc2\xa0$SRPT https://t.co/EGgOEiz2YM'
2021-01-08,"b""RT @JacobPlieth: The market doesn't buy $SRPT 's excuses. Quick take on Study 102 via @evaluatevantage https://t.co/T9soZA3K9p $PFE $SLDB"""
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,b'Staying away from $SRPT for the mean time'
2021-01-08,b'Big Loser Alert: Trading today\xe2\x80\x99s -48.6% move in SAREPTA THERAPEUTICS INC. COM\xc2\xa0$SRPT https://t.co/FdDk8ugPPq'
2021-01-08,b'$SRPT Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference https://t.co/e1rKoiGC77'
2021-01-08,b'$XBI doing fine with $SRPT collapse \xf0\x9f\xa7\x90'
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 765'
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 764'
2021-01-08,b'$CAPR On Q3 call in Nov \xe2\x80\x9820 said \xe2\x80\x9chaving active discussions with several potential strategic partners\xe2\x80\x9d. Assume $SRPT news gets those strategic partners closer to pot\xe2\x80\x99l deal with CAPR. Solid ~15% move so far but only 20mm sh outstanding. Strong cash bal. Q3 call comments attached. https://t.co/fCNr6StIM0'
2021-01-08,"b'(Heavy Volumes at 10x normal) $SRPT(Sarepta Therapeutics, Inc.) trading at $86.25, change today = -48.73% https://t.co/Xlh8EGiGjW'"
2021-01-08,b'#Nasdaq\xc2\xa0\xf0\x9f\x87\xba\xf0\x9f\x87\xb8\xc2\xa0Top\xc2\xa0Three\nGainers\n$KMPH \xe2\x86\x915.25\xe2\x86\x925.46\n$VRDR \xe2\x86\x910.21\xe2\x86\x920.25\n$VIHAW \xe2\x86\x913.36\xe2\x86\x924.54\nLosers\n$LSEAW \xe2\x86\x931.66\xe2\x86\x920.31\n$SRPT \xe2\x86\x9382.36\xe2\x86\x9286.60\n$DYNA \xe2\x86\x930.18\xe2\x86\x920.20\n[price\xc2\xa0\xe2\x89\xa5\xc2\xa020\xc2\xa2] [volume\xc2\xa0\xe2\x89\xa5\xc2\xa010k] [delayed\xc2\xa015\xc2\xa0minutes]\n#Gainers #Losers #USMarkets\nVisit:\xc2\xa0https://t.co/YnZ3SKqXcm'
2021-01-08,"b'Call/Put Highest % Volume Changes: Calls: $CNET, $FEZ, $IPOE, $SRPT, $EXEL  Puts: $SRPT, $IPOE, $XLP, $DDD, $ELAN'"
2021-01-08,b'$SRPT well I am sitting w profit but this bounce is super boring and market pulling back may put a damper on the bounce...for today at least. May have to hold for a little longer.'
2021-01-08,"b""The market doesn't buy $SRPT 's excuses. Quick take on Study 102 via @evaluatevantage https://t.co/T9soZA3K9p $PFE $SLDB"""
2021-01-08,b'ROCE Insights For Sarepta Therapeutics $SRPT https://t.co/vQEujyyhVH'
2021-01-08,"b""$SRPT \n Sarepta selloff on 'disappointing' data a buying opportunity, says Citi. Buy rating , $215 price target"""
2021-01-08,b'The *largest decliners in the premarket* for you to watch at the open: $SRPT $SLDB $ALDX $IMTE and $AMRS. https://t.co/l8oqrlBlxS'
2021-01-08,"b'RT @Bigapple2la: Pretty sure none of approved DMD drugs work, exon skipped or not.  FDA sometimes acts like a charity.  $PTCT $SRPT'"
2021-01-08,"b'RT @BosBizDon: As stock markets opened, shares of @Sarepta plunged by 50% after a placebo-controlled trial of its gene therapy meant to hel\xe2\x80\xa6'"
2021-01-08,"b'Stocks in Oversold today: $SRPT, Current Price: $85.6, Change today: -48.79%, Total Traded Volume: 8,063,012 https://t.co/ZDLzxXADxr'"
2021-01-08,b'Bearish breakout on $SRPT. Price broken 60 days low. Are you holding? https://t.co/zXRWsnXsPg #stocks https://t.co/7SggwWHCtw'
2021-01-08,"b'Stocks in Top Losers today: $SRPT, Current Price: $85.0, Change today: -48.79%, Total Traded Volume: 8,063,012 https://t.co/P3nMhKFnsl'"
2021-01-08,b'BTW $SRPT trials have always been sketchy!'
2021-01-08,b'$SRPT management announcing today that they are presenting at the JPM Biotech conference this Monday. Expect an explanation of the trial + pump to recover losses in the stock. https://t.co/lZ5saD37Lt'
2021-01-08,"b'$SRPT Stock still not pricing in possibility of losing exon-skipping revenue. Will probably bounce in this stupid market, but pandora\xc2\xb4s box has been opened.\n\nDystrophin in the future insufficient for DMD-approvals? \n\n$SLDB also possibly in vain'"
2021-01-08,"b'$SRPT Company has 1.8 billion in cash (buyback) + presentation on Monday to the JPM Health Care Conference. Lots of catalysts to gain some of this drop back. In the meantime, accumulation for smart money down here at 85.'"
2021-01-08,b'$SRPT Looks like the market just figured out that management is going to clarify the study and pump this stock back up on Monday at the conference.'
2021-01-08,b'$SRPT What a gift at $85!'
2021-01-08,b'@Pharmdca $srpt loss is $capr gain @biostockguru.'
2021-01-08,b'$SLDB should be down ~60-80%. $SRPT'
2021-01-08,b'$SRPT NEW ARTICLE : Serepta Stock Nearly Halves After Failed Gene Therapy Study https://t.co/hsJL2uUNnw Get all the latest $SRPT related news here : https://t.co/q0KoOem9rf https://t.co/OBFzAUj9zv'
2021-01-08,"b'@glenntongue $bmyrt - after things got dodgy following that first company disclaimer, yes I believe so\n$srpt - always'"
2021-01-08,b'#biotechs up nicely despite $SRPT'
2021-01-08,b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT \n\nContinued Rx with DMD GT will further improve functional dystrophin amount and NSAA at 180 wks.'
2021-01-08,b'@bioILLOGICAL Seems like $SRPT is a lot better at sales than science. Even most AAV based gene TX companies aren\xe2\x80\x99t getting hit on this news.'
2021-01-08,"b""@septdecoeur Yes, and it's unfortunate that $SRPT let it go despite the very large discrepancy in function for the Placebo cohort at baseline."""
2021-01-08,b'$SRPT Sarepta Therapeutics Option Order Flow Sentiment has Shifted from Bullish to Bearish. https://t.co/DUKh14PIkp'
2021-01-08,b'Grabbed some $SRPT at 84.90 then again 86.00 I wanna see where this pops up too! No options on this cuz it could stall or go sideways. https://t.co/KPDFl5wiI5'
2021-01-08,b'January 8th Biotech Update $_atnx $NBIX $SRPT $XBI https://t.co/KEjnX5YZ8c'
2021-01-08,"b""RT @Sanctuary_Bio: Reminder that $SRPT has done $333M in product sales first nine months of 2020, yet they still haven't completed the conf\xe2\x80\xa6"""
2021-01-08,"b""RT @Biotech2k1: $SRPT still proving you can't force round pegs (AAV) in square holes (muscle tissue). I think its a good thing for $RNA and\xe2\x80\xa6"""
2021-01-08,"b'Sarepta Craters, Cutting Market Value in Half on Therapy Miss $SLDB $MS $SRPT https://t.co/oCBTSbHeGT'"
2021-01-08,b'RT @ag76_biotech: -PMO platform producing 1% dystrophin \n-GT platform producing 28% dystrophin\n-Even 28% dystrophin production translates t\xe2\x80\xa6'
2021-01-08,"b""RT @Sanctuary_Bio: Reminder that $SRPT has done $333M in product sales first nine months of 2020, yet they still haven't completed the conf\xe2\x80\xa6"""
2021-01-08,b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT \n\n~175% improved functional dystrophin amount is enough https://t.co/75eV2WEJad'
2021-01-08,b'$srpt been whipping boy its whole existence'
2021-01-08,b'$SLDB just wow $$$ \nThank you again panic sellers &amp; $SRPT for that dropppppp \xf0\x9f\xa4\x91'
2021-01-08,"b'-PMO platform producing 1% dystrophin \n-GT platform producing 28% dystrophin\n-Even 28% dystrophin production translates to zero clinical efficacy\nIt appears both $Srpt platforms for DMD are useless, stock should be trading in the $25-$30 range reflecting 2B cash value'"
2021-01-08,b'$SRPT Sarepta Sinks on Disappointing Gene-Therapy Study Results\n\nhttps://t.co/OwZibom1xZ'
2021-01-08,b'@bradloncar have you seen that the 2 groups at baseline were significantly different? $srpt https://t.co/jHYEEbeY4R'
2021-01-08,b'Top Implied #Volatility Decliners $SRPT $EEM $MU https://t.co/xCUwW6yNvE'
2021-01-08,b'$SLDB up 25% since entry as expected. Recovering off $SRPT data. Should be up'
2021-01-08,"b'abstained from #ES_F today and pulling bank all morning trading common and options on $SRPT  A nice opp, w now a presentation at $JPM conference Monday'"
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 730'
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 700'
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 699'
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 698'
2021-01-08,"b'$crsp $edit $srpt $blue $beam $fate $ntla look at Sarepta today, this is what happen for long term investors if hold so long.'"
2021-01-08,b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT $CRSP\n\nFunctional dystrophin produced by GT &amp; crisper is same.'
2021-01-08,b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT\n\nQ is what was baseline amount of dystrophin and post GT Rx dystrophin ?'
2021-01-08,"b'After $SRPT setback yesterday, another day of surging gene editing stock prices:\n\n$CRSP +5% ($14.5B market cap)\n$BEAM +9% ($6.2B)\n$EDIT +7% ($6B)\n$NTLA +5% ($4.8B)'"
2021-01-08,"b'Optimus v4\n2021-01-08 10:00 ET. Bought/Opened:\n$SRPT at $85.04. \nSarepta Therapeutics, Inc (CORP).\nWin Chance: 71%. Avg Win: 3%. Avg Loss: 6.57%. Avg Hold: 7d.\nTrade Id: 63817138203004716.\nStats: https://t.co/oAX4hq6SAg'"
2021-01-08,b'got $SRPT call'
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT\n\nDMD GT expression is ~ 33% with &amp; dystrophin fiber % is 33%. https://t.co/3wKqwEEoxR'
2021-01-08,b'$SRPT Trading lower after the company reported its 102 Study Evaluating its SRP-9001 did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to Placebo at 48 weeks. https://t.co/XV3qf3bCO8'
2021-01-08,b'$crsp $edit $ beam $ntla $ fate $blue $srpt investors are so optimistic on these stocks and will be a result of Sarepta today diving.'
2021-01-08,"b'@SerSZ With the greatest of respect, I trade for a living and am not an advisor. But in the spirit of the moment, I bought some $SRPT after the bad clinical trial results when it reopened last night at 77 1/2ish. Otherwise, have made no purchases save hedging adjustments'"
2021-01-08,b'RT @adamfeuerstein: Updated --&gt; $SRPT gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome https://t.co/SdfYFxAm\xe2\x80\xa6'
2021-01-08,"b'$srpt all the explanation of the failed 102 study are in the baseline of6-7yo group! In the placebo, patients are significantly better only at the baseline!! https://t.co/Uq3wGQIzAJ'"
2021-01-08,"b'DOWNSIDE MOMO: $SRPT Sarepta Therapeutics, Inc https://t.co/VfZhwAb0wS \xf0\x9f\x93\x89 \xf0\x9f\x94\x9c TradeIdeas via \xe2\x9f\xb6 https://t.co/ZgCyz4rX3x'"
2021-01-08,"b'RT @_JamesBradley__: $SRPT $SPY initial short bias, 1 minute candle charts. Smaller size, it\xe2\x80\x99s Friday. Entered short at $84.27 9:31:58am mo\xe2\x80\xa6'"
2021-01-08,"b'$SRPT $SPY initial short bias, 1 minute candle charts. Smaller size, it\xe2\x80\x99s Friday. Entered short at $84.27 9:31:58am morphing inside candle and tape. Covered all at $83.24 at 9:32:10am. 12 seconds in the trade.  $785  @RobInTheBlack #TheStrat @CyberDog2 https://t.co/ceqsGIpcHj'"
2021-01-08,b'$SRPT -50%  Anyone care?  Yeah me neither'
2021-01-08,"b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT\n\nQ is what is important for #DMD patients, exact amount of dystrophin increased or % increase from baseline ?'"
2021-01-08,"b'$SRPT down 50%, bought a call \n\n01/15/2021\n80 C\n\nplaying it for a small recovery by next week'"
2021-01-08,"b""guy brags every 10 bucks about feeding his dog steak and scotch and how he is pressing.. then kaboom and crickets. bio guru's beware. $srpt"""
2021-01-08,b'#Ivy Science&amp;Tech fundholders worry about $SRPT collapse.'
2021-01-08,b'RT @PortfolioBuzz: These assets are seeing a jump in tweets #merger $MRNA $SRPT https://t.co/VY9KJhyAkH'
2021-01-08,b'$SPY $DIA $IWM $QQQ $IBB $XBI\n\n$SRPT\n\nQ: Whether GT SRP-9001 Micro-dystrophin produces functional dystrophin ?\n\nA: Yes'
2021-01-08,b'$SLDB could end the day green - \n\n#Street realizing $SRPT #Fail is net ++ for $SLDB\n\nSee my thread \xf0\x9f\x91\x87\xf0\x9f\x91\x87\xf0\x9f\x91\x87 https://t.co/HqvYWNQwZ5'
2021-01-08,"b'$SRPT Top-line results for Part 1 of Study 102 evaluating SRP-9001 for treatment of Duchenne Muscular Dystrophy, met primary endpoint but was not statistically significant; Secondary endpoints met (Sarepta)\n(More at https://t.co/is9o4CFmyI)\n(overnight)'"
2021-01-08,"b""Tommy O'Brien hosts the Morning Market Kickoff for Friday on @TFNN and discussed $RTY $CL $NG $ZN $BTC $TSLA $SRPT $TGT and more! #Financialeducation #Learningtotrade #StockMarketNews #TFNN #FridayFinance #RocketEquities #StocksToTrade\nhttps://t.co/4jcoVQFbIu https://t.co/ksp2a0sfQT"""
2021-01-08,"b'$SRPT let them puke it up, just to come on Monday and see a bid from Roche at $250 . The study was not a complete failure, most ignorant posts here are from morons and shorts thinking its going lower, it wont, this is the bes... https://t.co/PIcwA5ZJa3'"
2021-01-08,"b'RT @nixon786: $SRPT A: walking needs to be ""linked"" with ""functional"" protein production by objective tests. $IBB $XBI $SPY $DIA $IWM $QQQ'"
2021-01-08,"b'RT @nixon786: @sharkbiotech key questions for me,1) whether produced dystrophin is functional or not? &amp; 2) whether body is mounting immune\xe2\x80\xa6'"
2021-01-08,b'RT @nixon786: $SRPT longs. Whether $SRPT drug produces functional dystrophin or not ? 30 mcg dose produced the protein but did not improve\xe2\x80\xa6'
2021-01-08,"b'RT @nixon786: Question is same - whether produced dystrophin is ""functional"" or not? $SRPT. Quality is important &amp; not the quantity.'"
2021-01-08,b'These assets are seeing a jump in tweets #merger $MRNA $SRPT https://t.co/VY9KJhyAkH'
2021-01-08,b'$SRPT good entry at 84.30$?'
2021-01-08,b'$SRPT screwed you over? \n\nAvoid that. Trade up @ https://t.co/Ea0ZUUg4H6 \n\n#OOTT $TSLA $AAPL $NFLX $GOOG $NFLX https://t.co/s7x6FBe4f7'
2021-01-08,"b'@Bios_n_Techs @STL_Biotech @biotechinvstr $SRPT stoking up advocates while dragging feet on functional outcomes studies, well knowing that feeble surrogate changes are unlikely to translate into significant outcomes, is what makes the company so despicable'"
2021-01-08,b'@Bionerd51 So you believe the eteplirsen had benefit after less than 6 months w/ a fraction of dystrophin compared to SRP-9001? $SRPT'
2021-01-08,b'Gapping down via #Blarney\n$SPX $NDX\n#Earnings\n$VLDR -4.8% \n$NBIX -3.7%\n$ASX -0.6%\n#Biotechs\n$SRPT -47.5% \n$SLDB -20.4% \nStock offering\n$BNGO -7.6% ()\n$CERC -6.2%\n$BLNK -1.8% \nUpdate\nhttps://t.co/wwyssizYm1 https://t.co/6yj2tqj3IR'
2021-01-08,"b'Large Print $SRPT Size: 102200 Price: 84.85 Time: 938 Amount: $8,671,670.00'"
2021-01-08,b'$srpt case in point as to why I do NOT trade biotechs.  I will invest when I know the story and understand the clear risk.'
2021-01-08,b'$SRPT ...overreaction...many other shots at the goal.'
2021-01-08,"b'RT @BosBizDon: As stock markets opened, shares of @Sarepta plunged by 50% after a placebo-controlled trial of its gene therapy meant to hel\xe2\x80\xa6'"
2021-01-08,b'Top increases in # stock tweets per ticker yesterday:\n\n1) $TSLA +3988 (10694)\n2) $IPOE +2005 (2024)\n3) $PLUG +1951 (2640)\n4) $FTFT +1146 (1185)\n5) $DDD +945 (957)\n6) $MARA +860 (2388)\n7) $FCEL +584 (1082)\n8) $SRPT +545 (573)\n9) $TWTR +506 (978)\n10) $LMND +496 (598)'
2021-01-08,b'Oversold on Hourly  \rhttps://t.co/2Hf0ZbjpKC \r$DUK  91.46  to 89.74 \r$XEL  66.35  to 65.35 \r$FE  30.43  to 29.69 \r$SRPT  174.30  to 166.93 \r$ED  71.49  to 69.90 \r$D  74.80  to 73.03 \r$FDX  256.22  to 247.41 \r$CAG  35.70  to 3'
2021-01-08,"b'Optimus v4\n2021-01-08 09:34 ET. Bought/Opened:\n$SRPT at $84.78. \nSarepta Therapeutics, Inc (CORP).\nWin Chance: 66%. Avg Win: 5%. Avg Loss: 7.56%. Avg Hold: 9d.\nTrade Id: 63815629503068026.\nStats: https://t.co/oAX4hq6SAg'"
2021-01-08,"b'Optimus v4\n2021-01-08 09:34 ET. Bought/Opened:\n$SRPT at $84.78. \nSarepta Therapeutics, Inc (CORP).\nWin Chance: 65%. Avg Win: 5%. Avg Loss: 7.49%. Avg Hold: 9d.\nTrade Id: 63815629503068026.\nStats: https://t.co/oAX4hq6SAg'"
2021-01-08,"b'As stock markets opened, shares of @Sarepta plunged by 50% after a placebo-controlled trial of its gene therapy meant to help #Duchenne patients create the protein they lack failed to show benefit on muscle tests. Mkt. cap loses over $6B as a result. $SRPT https://t.co/WdNizpgGvE'"
2021-01-08,"b'RT @getvolatility: Unusual call buying: $XNET 30x average volume, $DDD 27x, $SRPT 19x, $URBN 15x, $IFF 14x, $JNK 12x, $CLNE 10x, $CROX 10x'"
2021-01-08,"b'Optimus v4\n2021-01-08 09:33 ET. Bought/Opened:\n$SRPT at $85.15. \nSarepta Therapeutics, Inc (CORP).\nWin Chance: 67%. Avg Win: 4%. Avg Loss: 5.41%. Avg Hold: 8d.\nTrade Id: 63815457903046902.\nStats: https://t.co/oAX4hq6SAg'"
2021-01-08,"b""$SRPT opens off 50%. Utterly disgusting. Don't these analysts care about the children???!! https://t.co/PsEMLBMYQL"""
2021-01-08,b'Pharmalot.. Pharmalittle.. Good Morning.. Pfizer-BioNTech vaccine seems to work against Covid-19 mutation; Sarepta gene therapy shows mixed results &amp; more news.. https://t.co/3WPp7KLgll #pharma #biotech #Covid_19 #coronavirus #vaccine $PFE $BNTX $RHHBY $SNY $MRN $JNJ $SRPT'
2021-01-08,"b'Unusual call buying: $XNET 30x average volume, $DDD 27x, $SRPT 19x, $URBN 15x, $IFF 14x, $JNK 12x, $CLNE 10x, $CROX 10x'"
2021-01-08,b'@rolf_widerhofer @DrPaulyDeSantis Lol 4 patients study very large population. It reminds me $SRPT phase 1 study'
2021-01-08,b'$SRPT double downgrade.\n\nUnderweight from Overweight at JPMorgan.'
2021-01-08,"b""Europe Mixed, Asia Up &amp; US To Open Up, World Covid-19 Cases 88M (US Cases 21.6M), Dec. Jobs at -140K w/ +50K Exp'd, $BA Hit With $2.5B Fine, $SRPT Gene Therapy Miss, Earnings: $MU Beat, S&amp;P to open 3815, Gold $1888, Silver $26.70, 10yr yield 1.08, Dollar (DXY 89.68), Oil $51.60"""
2021-01-08,b'@sharkbiotech $SRPT Wise words!'
2021-01-08,b'$SRPT \nMaintains SVB Leerink Outperform USD 197 \xc2\xbb USD 125\nTarget Lowered by Barclays Positive \xc2\xbb Overweight USD 192 \xc2\xbb USD 125\nMaintains Needham &amp; Company LLC Buy USD 182 \xc2\xbb USD 166\nDowngraded by Raymond James Financial... https://t.co/ll2qdx3b8d'
2021-01-08,b'$SRPT hit the 78 support watch the 71 support $BYND hit 116 area watch 121.87 break area $W broke the 247.59 next is about 257 resistance $NVDA watch for 539 break'
2021-01-08,b'RT @adamfeuerstein: Updated --&gt; $SRPT gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome https://t.co/SdfYFxAm\xe2\x80\xa6'
2021-01-08,"b'Have people thought that maybe the only reason there is small effect in the 4-5 age group is because of small N? The same reason why phase-1 was successful, magic of very small N\n\nThere is no correlation between dystrophin production and clinical efficacy, $srpt'"
2021-01-08,"b'RT @ITMS: TRADES TO TAKE: \n\n$SRPT, $TSLA, #Banks, #Yields, #Oil And More...\n\nhttps://t.co/puF2BK255L'"
2021-01-08,"b""$srpt... isn't the fall hair cut over done..Sarept is not on about gene therapy..there is RNA for which drugs are on the market..."""
2021-01-08,b'Pre-Market Watchlist \nUp: $MU $TSLA $FTFT $FCEL $NIO \nDown: $SRPT $UBER  \n \nTrade these tickers with me LIVE at https://t.co/jWUn8mD4XK'
2021-01-08,b'Sarepta downgraded to Underweight from Overweight at JPMorgan\n$SRPT'
2021-01-08,b'And just like that $6bn evaporated $SRPT'
2021-01-08,"b'@adamfeuerstein @zbiotech Some dystrophin is better than no dystrophin\nFailure to approve a drug to prevent a progressive disease puts patients at risk of irreversible loss of function\nBeen out of $SRPT for a long time, but company has still benefitted thousands of #DMD patients. \nEUA for vaccines like AA'"
2021-01-08,"b""RT @STL_Biotech: @biotechinvstr $SRPT What exactly is worth $5B over cash here? Similarly 4.5B over cash at $SAGE. I get that there's some\xe2\x80\xa6"""
2021-01-08,b'RT @biotechinvstr: Strong words from Guggenheim analyst who called the $SRPT fail. Point 2 is what should evaporate any hope in the dystrop\xe2\x80\xa6'
2021-01-08,"b""RT @biotechinvstr: Was a key point slipped into last night's cc but missed by most.\n$SRPT still at $7B market cap, with mounting evidence o\xe2\x80\xa6"""
2021-01-08,"b'Sarepta Therapeutics ( $SRPT ) announced mixed results from the first randomised clinical trial of its gene therapy for Duchenne muscular dystrophy, raising questions about the path forward for the one-time, potentially curative treatment.'"
2021-01-08,b'$jakk jakks pacific may announce new financing deal in the near future. CEO-Stephan Berman and CFO-John Kimble are working hard for this. \xf0\x9f\x92\xaa\n@JAKKStoys\n$cmrx $rive $occ $mrus $scor $srpt $sldb $nltx $grin $tsla $amzn $aapl $fcel $xnet $nasdaq #xauusd #xagusd #eurusd'
2021-01-08,b'RT @TerriEllsworth: @BiotechPort @adamfeuerstein My son turned 20 yesterday and has been on #eteplirsen since 2011. He is still very ambula\xe2\x80\xa6'
2021-01-08,b'RT @smbcapital: Stocks the desk is watching: $SRPT $VLDR $DDD $NIO $TSLA https://t.co/beEuqgddPC'
2021-01-08,"b'RT @biotechinvstr: Now that first RANDOMIZED trial testing ""higher"" dystrophin hypothesis failed, interesting to see what FDA does--if CRL\xe2\x80\xa6'"
2021-01-08,"b""@biotechinvstr $SRPT What exactly is worth $5B over cash here? Similarly 4.5B over cash at $SAGE. I get that there's some residual value but a cumulative 10B for 2 bios where the central thesis is toast (IMO) seems a bit rich."""
2021-01-08,b'Stocks the desk is watching: $SRPT $VLDR $DDD $NIO $TSLA https://t.co/beEuqgddPC'
2021-01-08,"b'RT @MedResCol: (1/4) $SRPT A few observations.  \n\n~67% were in the 6-7 age group, and ITT was +1.7 v. +0.9 (tx v. pbo) at wk48, and 4-5yr o\xe2\x80\xa6'"
2021-01-08,b'@skaushi Is it typo $spr or $srpt?'
2021-01-08,b'RT @biotechinvstr: Strong words from Guggenheim analyst who called the $SRPT fail. Point 2 is what should evaporate any hope in the dystrop\xe2\x80\xa6'
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,"b'TRADES TO TAKE: \n\n$SRPT, $TSLA, #Banks, #Yields, #Oil And More...\n\nhttps://t.co/puF2BK255L'"
2021-01-08,"b""My watchlist for the 8th\n\nGapping up: $ACIA, $NKLA &amp; $NIO\n\nGapping down: $SRPT, $DDD &amp; $UBER\n\nI reviewed my rules and strategy; I'm staying away from stocks with a large spread, exiting as soon as a trade is not moving as I anticipated and respecting my stop.\n\nLet's go!!"""
2021-01-08,b'$SRPT 15-Jan-21 Straddle Implies a \xc2\xb126.0% move. Jan 11 39th Annual J.P. Morgan Healthcare Conference https://t.co/zSEXcX5CZu'
2021-01-08,"b'$SRPT.. Lackluster DMD data point toward pushed out launch data, tempered uptake expectations. $PFE now ahead in the race...\n\nhttps://t.co/njUoxonTQk'"
2021-01-08,"b'$BBBY +4,5% PM\n$MU +4%PM ON EARNINGS\n$OEC +14% PM\n$SRPT - 52% PM\n$UBER - 5% PM\n$AEHR - 14% PM ON EARNINGS'"
2021-01-08,b'$PFE should benefit from the $SRPT news. $SRPT has been delaying this for so long now i dont think we will see a recovery soon.'
2021-01-08,b'RT @TerriEllsworth: @BiotechPort @adamfeuerstein My son turned 20 yesterday and has been on #eteplirsen since 2011. He is still very ambula\xe2\x80\xa6'
2021-01-08,"b'Early premarket gappers \n\nGapping down:  \n\n$SRPT -48.4%, $SLDB -17.5%, $BNGO -14%, $VLDR -6.5%, CERC -6.2%, $SGH -4.9%, $UBER -3.9%, $PME -3.8%, $CS -2.7%, $ARGX -1.4%, $SYRS -1.1%, $EPR -1%, $MOD -1%, $NVAX -0.9%, $JFIN -0.9%, $LYFT -0.7%, $ASX -0.6%'"
2021-01-08,b'RT @sciencescanner: No-one is sadder than me for the patients and their families whose hopes are dashed. We are all in this business to mak\xe2\x80\xa6'
2021-01-08,b'RT @sciencescanner: I wonder how many failures it will take before $SRPT and their investors read my QJM Editorial from 2000 (https://t.co/\xe2\x80\xa6'
2021-01-08,"b'Strong words from Guggenheim analyst who called the $SRPT fail. Point 2 is what should evaporate any hope in the dystrophin hypothesis, and point 4 calls into question whether even the contrived subset analysis data profile is viable https://t.co/9pn8n4g5nw'"
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,b'Recent $SRPT technical alerts: Pocket Pivot plus 9 more alerts... https://t.co/GDjdQQi59A'
2021-01-08,b'$AMZN $BIDU $ROKU $TSLA are top 4 watches on the day.\nMight watch $SRPT to get the blood flowing a bit.'
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,"b'RT @TradenetAcademy: President Donald Trump Concedes | Key US Jobs Data: https://t.co/x7ohOHmx94\n\n$SRPT, $TSLA, $FFIV, $GT, $NIU, $MU, $SWI\xe2\x80\xa6'"
2021-01-08,"b""RT @zbiotech: RJ analyst: 'And then, I might have missed this, but did you see any correlation with mean dystrophin expression and NSAA sco\xe2\x80\xa6"""
2021-01-08,"b""This Morning's Top 5 Decliners Report:\n$SRPT (-50%)\n$BNGO (-21%)\n$SLDB (-20%)\n$CTRM (-19%)\n$NLTX (-18%)\n\nAlerts, Charts, and Technical Analysis via https://t.co/Qkw92RLxV8\n#daytrading #stocks"""
2021-01-08,"b""Today's Watchlist - $PDD $AMD $BIGC $UBER $NEM $BBBY $SPCE $FSLY $CRSR $SRPT $BYND. https://t.co/C62U13wWE3"""
2021-01-08,"b""Today's #Market Movers Higher: $TSLA, $MSTR, $BIDU, $ACIA, $BNTX, $ROKU, $ENPH, $TTD, $SNOW, $MU, $TSM, $NEWR, $FFIV\n \nToday's #Market Movers Lower: $SRPT, $NBIX, $UBER, $LMND, $NEM, $DDD, $GLD, $AEM, $YY, $TDOC, $RACE"""
2021-01-08,b'$SRPT recovery is gonna be 1/2 -1 year... see you guys at $20s and below'
2021-01-08,b'$SRPT -47.5% (reports data for SRP-9001 for the treatment of Duchenne; primary endpoint did not achieve statistical significance) \n\n$SLDB -20.4% (in sympathy with clinical data release from SRPT)'
2021-01-08,b'small-starting position in $SRPT 83.83$'
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,"b""(4/4) I think (b), given that the baseline NSAA of the 6-7 yr old tx group was 19.6 and that of 4-5 yr old tx group was a very close 20.1. \n\nThis lack of disclosure is in character for $SRPT, as we've seen with their burying of the failed PROMOVI results. \n\n(no position)"""
2021-01-08,"b'(3/4) $SRPT We may conclude either (a) increasing m-dys by 28% is effective in 4-5 year olds but suddenly stops working in 6-7 yr olds; or (b) inc m-dys 28% is clinically irrelevant, and the effect seen in 4-5 year olds is a biased result due to very small n.'"
2021-01-08,"b""(2/4) PBO in 6-7 gr is also calculable for wk48, and is = w/ tx group at +0.41, as 0.33 * 1.90 = 0.63, so blended +0.90 gives delta of 0.27, and 0.67 * 0.41 = 0.27.\n\nHence $SRPT 's timidity in showing these data; PBO group was = w/ 9001 in 6-7 year olds. \n\nhttps://t.co/VW79UjVe2H"""
2021-01-08,"b'(1/4) $SRPT A few observations.  \n\n~67% were in the 6-7 age group, and ITT was +1.7 v. +0.9 (tx v. pbo) at wk48, and 4-5yr olds were +4.3 v. +1.9. Thus, 6-7 yr old tx group NSAA at wk48 was +0.42, as 0.33 * 4.3 = 1.42, so blended +1.70 gives delta of 0.28, and 0.67 * 0.42 = 0.28.'"
2021-01-08,b'Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint $SRPT $PFE $SLDB https://t.co/kHQzIafkCQ'
2021-01-08,b'RT @FSTrades: $SRPT -50% after mixed results for gene therapy in muscular dystrophy https://t.co/1F8t9Pgruq'
2021-01-08,b'140K jobs were lost in December primarily because of the COVID-19 spread. \n\nLong watches $MU $BIDU $MARA $PLUG $NIO $XPEV $STM \n\nIf you desire bottom fishing look at $SRPT which closed yesterday at $168.90 and is down a mere 49% in the premarket.'
2021-01-08,"b""Was a key point slipped into last night's cc but missed by most.\n$SRPT still at $7B market cap, with mounting evidence on a complete lack of correlation between dystrophin/u-dystrophin and functional benefit https://t.co/0l6o6FHbz2"""
2021-01-08,b'RT @NedPagliarulo: $SRPT gene therapy misses primary functional endpoint -- treatment did not result in a statistically significant differe\xe2\x80\xa6'
2021-01-08,b'NEWS 01/08/2021: $SRPT Sarepta Therapeutics (SRPT) \xe2\x80\x93 Sarepta gene therapy treatment for Duchenne muscular dystrophy did not meet one of its main goals in a study.'
2021-01-08,b'$sldb falling over 20% in sympathy with $Srpt? Or their drugs have same mechanism of action?'
2021-01-08,"b""Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves.  VI will select up to 4 stocks per day.  Today's VI stocks:  $FFIV, $MU, $SRPT, $WDFC.  To learn more, visit our site, watch the video, and sign up for free!\n\nhttps://t.co/9wneaQvcP2"""
2021-01-08,"b'RT @franklin19788: No longer in $srpt but it will always have a special place in my heart, especially 2012. Will always wish them well. htt\xe2\x80\xa6'"
2021-01-08,b'Tickers trending on TWTR in last 1 hour $AZN $MRNA $MU $SRPT https://t.co/6Y9aO8V57P'
2021-01-08,b'These wall street analysts are pathetic..raymond James and JPM downgrading $Srpt after this epic fall!? Come one now.. piling on the pain!'
2021-01-08,"b""RJ analyst: 'And then, I might have missed this, but did you see any correlation with mean dystrophin expression and NSAA scores?'\n\nIngram: 'To the best of our knowledge right now, no'\n\n$SRPT"""
2021-01-08,b'All these small N trials that have driven up valuations have always scared me. What\xe2\x80\x99s happening to $srpt was bound to happen eventually. No position but I feel bad for the Longs.'
2021-01-08,"b'$srpt.. oh boy, this ticker is being clobered this AM. Any chance of rebound in regular session.. As if apocalypse is near!?'"
2021-01-08,b'RT @jonnajarian: \xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7\xe2\x80\xa6'
2021-01-08,"b'Now that first RANDOMIZED trial testing ""higher"" dystrophin hypothesis failed, interesting to see what FDA does--if CRL Feb 25 casimersen PDUFA.. \nRecall FDA dinged $SRPT in 2013 for *Prosensa* fail, they DO look at evolving evidence around surrogate biomarkers and clin relevance https://t.co/s8gTkr49us https://t.co/sFSYmYugqY'"
2021-01-08,"b""If the drop for $SRPT holds it'll wipe out roughly $6.7 billion in market value and put shares back where they were in the March market bottom. Rough start for biotech in 2021 after an astounding 2020 https://t.co/FFiCCYpEzf"""
2021-01-08,b'@pennystocksusa I havent said anything about $SRPT?'
2021-01-08,b'Good Morning Traders Some Tickers that have my interest this morning\n$LGHL\n$FTFT\n$VIH\n$MARA\n$PLUG\n$QS\n$SRPT\n$BNTX\n$SNOW\n$BIDU\n$NVDA\n$TSLA\n$NIO\nTo name a few plays\nCurrently 67 on MY list narrowing it down to the Final 12 for Clients Going to Be Fun\nJOIN US\nhttps://t.co/Lp58JbFkKW https://t.co/m2D4XR9HRo'
2021-01-08,b'\xe2\x8f\xb1\xef\xb8\x8f60 Seconds Elvis\xf0\x9f\x95\xba86 $TSLA $MU $BA $SRPT $AAPL 4MU see you on @3at3_UOA always more at \xf0\x9f\x91\x89 @MarketRebels https://t.co/xM3t7bxVOQ'
2021-01-08,b'RT @Bios_n_Techs: $BIIB Biogen Treats First Patient in Study of SPINRAZA to Treat Children With Spinal Muscular Atrophy.  $SRPT'
2021-01-08,b'@getbillasap pumping $SRPT on twitter this morning \xf0\x9f\xa4\xa3\xf0\x9f\x98\x98 https://t.co/qLLDFs5SIW'
2021-01-08,"b'@Zen_Options I have had my eye on $SRPT too. Could be a huge buying opportunity for leaps. Do you agree, or would you recommend waiting to see where the dust settles?'"
2021-01-08,"b'Sarepta Therapeutics\xc2\xa0( $SRPT ) shares plunged, losing nearly half their value. https://t.co/46xzeTwGAC'"
2021-01-08,"b'$srpt Sarepta Therapeutics (SRPT) Says Part 1 of Study SRP-9001-102 Met Primary Endpoint, But Did Not Achieve Statistical Significance in NSAA Total Score Improvement'"
2021-01-08,b'RT @_B_I_O_T_E_C_H_: JPM $SRPT We\ncontinue to see upside to the ~$205-225/share range on positive Study-102\nresults (or ~45-65%+ upside fro\xe2\x80\xa6'
2021-01-08,"b'President Donald Trump Concedes | Key US Jobs Data: https://t.co/x7ohOHmx94\n\n$SRPT, $TSLA, $FFIV, $GT, $NIU, $MU, $SWI &amp; more...\n\n#News #Headlines #Stocks #StockMarket #Equities #Finance #Investing #Trading #DayTrading #NYSE #NASDAQ #WallStreet https://t.co/ba2ptMkrAZ'"
2021-01-08,b'$SRPT -50% after mixed results for gene therapy in muscular dystrophy https://t.co/1F8t9Pgruq'
2021-01-08,b'@BiotechObserver $SRPT\nPrespecification today is the new best excuse of any shitty Biotech that fails trial.\nJust prespecify a bunch of sub groups and then use one that hits by chance to spin the data.\nNot going to fly with FDA.'
2021-01-08,"b'Slept in today and missed the best part of the crash, but picked up some $SRPT. Company working on Muscular Dystrophy treatments had its stock crash on mixed results. BUT, read the full presser, outperformed placebo and they are fairly aware of the protein issue that caused it.'"
2021-01-08,b'BAIRD $SRPT Our Study 102 Thesis Was Wrong but GT Program Remains Very Much Alive'
2021-01-08,"b""Most active stocks in today's pre-market trading\n\nTesla $TSLA\nApple $AAPL\n$NOV\nSarepta $SRPT\n$UBER\nAmerican $AAL\nAT&amp;T $T\n$GE\nMicron $MU\nCarnival $CCL\nPfizer $PFE\n$AIV\nMGM Resorts $MGM\n$BAC\nAramark $ARMK\n$AMD\nModerna $MRNA\nBoeing $BA\nVirgin Galactic $SPCE\nDraftkings $DKNG\n$ROKU"""
2021-01-08,b'lower high short setup ...on $SRPT   easy borrow too https://t.co/Ecs5JcJ8N4'
2021-01-08,b'easy entry setup on $SRPT  ... missed......just going thru my premkt runs'
2021-01-08,"b'Stocks with expensive options (high IV/IV percentile)  watch-list for Jan 08, 2021 $QQQ $SPY $IWM #success #trading #options #stock\n$JD $BABA $SPOT $XLNX $PDD $AMBA $NET $PINS $EDIT $SRPT https://t.co/9ocfCme63B'"
2021-01-08,b'$SRPT Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference\nFrom our Stock News Alerts App'
2021-01-08,"b'RT @biotechinvstr: the ""bad luck"" argument from $SRPT management and sellside is ridiculous. There were only 2 centers involved in the 102\xe2\x80\xa6'"
2021-01-08,"b""Today's Pre-Market Movers &amp; News [Friday, January 8th, 2021]: $TSLA $MU $BA $SRPT $AAPL $PFE $SWI $NIU $PSMT $FFIV $GT $MSTR $DHI #SPX #SPY CHARTS &amp; DISCUSSION! -&gt; https://t.co/fPZ33PJcQ8 &lt;- https://t.co/c7AbkCQUKC"""
2021-01-08,b'RT @biotechinvstr: This was an excellent prescient analysis done by Debjit at Guggenheim which pretty convincingly showed that the 9001 Ph1\xe2\x80\xa6'
2021-01-08,b'$SRPT rebajado a Equal Weight en Morgan Stanley. PT $ 95'
2021-01-08,b'Watching $srpt good price to enter?'
2021-01-08,"b'$SRPT [15s. delayed]: Issued Press Release on January 08, 08:30:00: Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference https://t.co/mTVMXRk5ip'"
2021-01-08,"b""RT @ByJonGardner: In the clear light of the morning after: Why wouldn't the FDA be interested in the $SRPT GTx therapy in the 4-5 group?"""
2021-01-08,b'$SRPT My pt is $90 at least today. Not falling for the pm antics.'
2021-01-08,b'$SRPT Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference\nhttps://t.co/9PkErLqPbA'
2021-01-08,"b""In the clear light of the morning after: Why wouldn't the FDA be interested in the $SRPT GTx therapy in the 4-5 group?"""
2021-01-08,"b'the ""bad luck"" argument from $SRPT management and sellside is ridiculous. There were only 2 centers involved in the 102 study. \nThe other ridiculous claim is the ""titering"" explanation for why the micro-dystrophin expression fell off a cliff https://t.co/lSO8JwQ8Ve https://t.co/8rsQnBlgEK'"
2021-01-08,b'$SRPT HEDGE SHORTS PRESSING and can easily shake out a few top hedge longs which is the game \xf0\x9f\xa9\xb8 https://t.co/oG3L8bd8bz'
2021-01-08,b'$SRPT  This exactly why I only trade verticals now.  For this very reason.   I still hsve 21 days to manage the position.'
2021-01-08,"b'$SRPT is at $87 right now, 48% drop. Look at these price targets from major banks. Charts show bounce to $105 today. Extreme oversold conditions, PT targets stable at the major banks over $140 or 70% return. https://t.co/hTQtE7iFcD'"
2021-01-08,b'$SRPT gapping down 50%. This is a large cap biotech. I am in this stock with an average cost of $140. it is blowing through my stop and i am losing 2x my risk. This is why i only risk .5% to 1% per trade b/c ANYTHING CAN HAPPEN!!!'
2021-01-08,b'Stocks Making The Biggest Moves PM: $TSLA $MU $BA $SRPT $AAPL $PFE $SWI $NIU $PSMT $FFIV $GT $MSTR $DHI &amp; More https://t.co/kWmbDDBfkm'
2021-01-08,b'RT @OpenOutcrier: $SRPT (-48.2% pre) Sarepta Crashes On Mixed Results For Gene Therapy In Muscular Dystrophy - IBD\n\nhttps://t.co/sJ49hqldU4'
2021-01-08,"b'@jeremyfaust I felt that way (much less importantly, of course) on $SRPT\n\nhttps://t.co/wlOXjoMkRI'"
2021-01-08,b'RT @biotechinvstr: This was an excellent prescient analysis done by Debjit at Guggenheim which pretty convincingly showed that the 9001 Ph1\xe2\x80\xa6'
2021-01-08,b'RT @jq1234t: @Ogut_Ozgur @EvenWangMD @Sports_bios This raises the question how could $SRPT use these biomarker data as comparability criter\xe2\x80\xa6'
2021-01-08,"b""$NLTX, $SRPT 12 Health Care Stocks Moving In Friday's Pre-Market Session - https://t.co/f4GUslO6Fb"""
2021-01-08,b'RT @biotechinvstr: This was an excellent prescient analysis done by Debjit at Guggenheim which pretty convincingly showed that the 9001 Ph1\xe2\x80\xa6'
2021-01-08,"b""This was an excellent prescient analysis done by Debjit at Guggenheim which pretty convincingly showed that the 9001 Ph1 data was an artifact in every sense. \n$SRPT cherrypicked 4 patients most likely to show benefit in an open label study. That's it. https://t.co/dygK15Rrh6 https://t.co/f1z5b9CRdw"""
2021-01-08,"b'$SRPT wow, not a bio guy but this must have been important to their pipeline. Maybe a little over done? $77 area that last line of defense. https://t.co/U9S8Rop6Fo'"
2021-01-08,"b'@JohnIII39374266 @humour_humourrr Less overnight binary risk like $srpt last night, but commercialization efforts often underperform expectations and pretty common for mrkt to treat approvals as sell the news events.'"
2021-01-08,"b'$SRPT only dumbass sell this stock. Basically if you can\xe2\x80\x99t read, you will sell. This company will makes more money than before if you know what it means.'"
2021-01-08,b'$SAIL\nSAIL Target Raised by The Goldman Sachs Group with price target $53.00 \xe2\x9e\x9d $61.00 and rating Buy\nSource:https://t.co/cLuXiVHuP1\n\n$SRPT\nSRPT Downgraded by Raymond James  and rating Outperform \xe2\x9e\x9d Market Perform | SR... https://t.co/asiliJvfIu'
2021-01-08,b'$SLDB (-20.4%) in sympathy with clinical data release from $SRPT'
2021-01-08,b'$SRPT (-47.5%) reports data for SRP-9001 for the treatment of Duchenne; primary endpoint did not achieve statistical significance'
2021-01-08,b'RT @adamfeuerstein: This is a reminder that $SRPT has still not demonstrated definitive clinical benefit for any of its APPROVED Duchenne d\xe2\x80\xa6'
2021-01-08,b'$SLDB (-17.8% pre) Soild Bio sinks after Sarepta $SRPT data misses goal - SA\n\nhttps://t.co/aWOvG3qE3u'
2021-01-08,b'$SRPT (-48.2% pre) Sarepta Crashes On Mixed Results For Gene Therapy In Muscular Dystrophy - IBD\n\nhttps://t.co/sJ49hqldU4'
2021-01-08,b'RT @BioStocks: $SRPT downgraded to Equal Weight at Morgan Stanley. PT $95'
2021-01-08,b'@JIMROInvest are u keeping your $srpt? thanks'
2021-01-08,b'RT @ej23ny: @JohnCendpts @Biotech2050 Lol $SRPT the first fool \xe2\x80\x9cRaymond James analyst Danielle Brill reiterated an Outperform rating and $2\xe2\x80\xa6'
2021-01-08,b'$SRPT double downgraded at JPM to underweight\ndowngraded to EW at MS and RayJay\nPT lowered to 73 and 81 at CS and Gugg respectively https://t.co/KzCF9vGHwQ'
2021-01-08,b'RT @adamfeuerstein: Baird analyst Brian Skorney on $SRPT: \xe2\x80\x9cOur call on Study 102 was as wrong as could be.\xe2\x80\x9d\n\nI respect Brian for his honest\xe2\x80\xa6'
2021-01-08,"b'Premarket tickers on watch: $TSLA $BIDU $SNOW $SRPT $RIOT $JAGX\n\nPre-market breakdown everyday 8:00-9:30am EST. Breakdown of the Macro Environment, Market, Commodities, FAANG and then Individual names. Action plan for open, being charted &amp; written Live.\n\nhttps://t.co/63TBxT5R0E'"
2021-01-08,b'$BIIB Biogen Treats First Patient in Study of SPINRAZA to Treat Children With Spinal Muscular Atrophy.  $SRPT'
2021-01-08,b'RT @jq1234t: 1Q21 Catalysts:\n\n$AGIO Mitapivat Transfusion Dependent PKD ph3\n$BMRN Valrox Hemophilia A ph3\n$BMY Relatlimab(anti-LAG3) 1L Mel\xe2\x80\xa6'
2021-01-08,b'RT @alphatrends: the unique risks of biotech stocks\n\nthe serpent $SRPT strikes again!  this one has been on my permaban for a decade\n\nlook\xe2\x80\xa6'
2021-01-08,b'RT @RNAiAnalyst: $SRPT primary functional efficacy misses despite robust gene therapy-mediated (micro-)dystrophin expression. Now: who stil\xe2\x80\xa6'
2021-01-08,"b'$SRPT totally agree, I thought they were suppose to release more clinical data on the conditional approval drugs. https://t.co/JLCgEb4M5z'"
2021-01-08,b'RT @adamfeuerstein: This is a reminder that $SRPT has still not demonstrated definitive clinical benefit for any of its APPROVED Duchenne d\xe2\x80\xa6'
2021-01-08,b'$SRPT interesting...hedge shorts are not covering at this moment'
2021-01-08,"b'Stocks making the biggest moves in the premarket: Tesla, Micron Technology, Sarepta Therapeutics &amp; more\nhttps://t.co/fCfklNDhQV\n\n$TSLA $FB $MU $BA $SRPT $AAPL $PFE $BNTX $SWI $NIU $PSMT $FFIV $GT $MSTR $DHI'"
2021-01-08,b'$SRPT (-47.6%) after providing disappointing top-line results for its Part 1 study to treat muscular dystrophy.'
2021-01-08,b'Congrats $srpt https://t.co/EyS4v9H7gU'
2021-01-08,b'tough day ahead for $SRPT Sarepta Therapeutics (-45% premarket)\n\nCredit Suisse cuts TP to $73 from $156\nJP Morgan cuts TP to $96 from $185\nMizuho cuts TP to $158 from $204\nPiper Sandler cuts TP to $140 from $240\nRBC cuts TP to $143 from $200\nSVB Leerink cuts TP to $125 from $197'
2021-01-08,b'$SRPT Sarepta price target lowered to $125 from $192 at Barclays \n\n#stocks #NASDAQ \nhttps://t.co/QT7pBUYaHU'
2021-01-08,b'@lglmrc And quite frankly with $SRPT failure these partnership Discussions probably just became much more lucrative.  $CAPR'
2021-01-08,b'$SRPT Over reaction - Add people'
2021-01-08,b'Me and my $srpt boys who also own shitcoins this morning https://t.co/70L19C7M2R'
2021-01-08,b'$SRPT hit $89 3 times already. Big wall?'
2021-01-08,"b'$SRPT\nToday is a great opportunity to sort out who are the decent Sell Side analysts with professional integrity,  and who are just.....'"
2021-01-08,b'$SRPT  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 447'
2021-01-08,b'\xf0\x9f\xa4\x94 dead cat?!?!? $SRPT interesting https://t.co/guG2pwQjAy'
2021-01-08,b'Sarepta price target lowered to $114 from $213 at Cowen\n$SRPT'
2021-01-08,"b""It was close. I didn't get in on this puppy only because I didn't have money.\nLook what is happening this morning because of $SRPT"""
2021-01-08,"b'RT @adamfeuerstein: Biotech 2021 has started off\xe2\x80\xa6 not so hot. \n\nLast night, $SRPT \xe2\x80\x99s gene therapy setback.\n\nThis morning, a SPAC deal that\xe2\x80\xa6'"
2021-01-08,"b'RT @adamfeuerstein: Biotech 2021 has started off\xe2\x80\xa6 not so hot. \n\nLast night, $SRPT \xe2\x80\x99s gene therapy setback.\n\nThis morning, a SPAC deal that\xe2\x80\xa6'"
2021-01-08,b'$SRPT\nTherapeutics Shares Down 48.5% Premarket; Co. Late Thursday Reported Study 102 Evaluating SRP-9001 Did Not Achieve Statistical Significance On The Primary Functional Endpoint Of Improvement In NSAA Total Score Compared To Placebo.'
2021-01-08,"b'RT @adamfeuerstein: Biotech 2021 has started off\xe2\x80\xa6 not so hot. \n\nLast night, $SRPT \xe2\x80\x99s gene therapy setback.\n\nThis morning, a SPAC deal that\xe2\x80\xa6'"
2021-01-08,"b'Biotech 2021 has started off\xe2\x80\xa6 not so hot. \n\nLast night, $SRPT \xe2\x80\x99s gene therapy setback.\n\nThis morning, a SPAC deal that is\xe2\x80\xa6 \xe2\x80\x9cgross\xe2\x80\x9d is the adjective that comes to mind. \n\nCellularity going SPAC-public at $1.7b valuation!?!?!\n\nhttps://t.co/G8gsk8twlE'"
2021-01-08,b'$SRPT find its way back to $100'
2021-01-08,b'RT @semodough: GUGG $SRPT - Is Micro-Dystrophin GTx the New Beta-Amyloid? PT Reduced to $81'
2021-01-08,"b'$SRPT Ingram broadcast the difficulty in demonstrating clinical benefit within 2 years when over a year ago SRPT increased the Phase III trial ""N"" significantly. Unfortunately 2 years is not enough time to demonstrate stat sig. i voiced my opinion a week ago and I was creamed.'"
2021-01-08,b'Don\xe2\x80\x99t beat yourself too much if you were long $srpt like I was.  There were a lot of good reasons to think the trial would be positive. Roche thought so.  There were good reasons to be skeptical as well. Sometimes it just doesn\xe2\x80\x99t work out. Not betting too big is key.'
2021-01-08,b'* SAREPTA THERAPEUTICS DOWNGRADED TO MARKET PERFORM FROM OUTPERFORM AT RAYMOND JAMES\n$SRPT https://t.co/lQxjIYFFFa'
2021-01-08,b'*SAREPTA THERAPEUTICS SHARES DOWN 48.5% PREMARKET; CO. LATE THURSDAY REPORTED STUDY 102 EVALUATING SRP-9001 DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON THE PRIMARY FUNCTIONAL ENDPOINT OF IMPROVEMENT IN NSAA TOTAL SCORE COMPARED TO PLACEBO AT 48 WEEKS POST-TREATMENT\n$SRPT'
2021-01-08,"b""Looks like some people still haven't figured out that the US $OCC isn't benefiting from the collapse of $SRPT.  They have it confused with an Australian company called #Orthocell that trades on the ASX with the symbol $OCC"""
2021-01-08,b'RT @dfwbiotechguy: Don\xe2\x80\x99t understand sell sides view on $srpt. The past approvals were conditional on Phase 3 completion. Today\xe2\x80\x99s trial show\xe2\x80\xa6'
2021-01-08,b'RT @adamfeuerstein: Baird analyst Brian Skorney on $SRPT: \xe2\x80\x9cOur call on Study 102 was as wrong as could be.\xe2\x80\x9d\n\nI respect Brian for his honest\xe2\x80\xa6'
2021-01-08,b'RT @shanthirex: $SRPT $CMRX $MRUS $CLSD and more\n\nBiotech stocks on the move...\n\nhttps://t.co/RibRmo0gis'
2021-01-08,b'RT @dfwbiotechguy: Don\xe2\x80\x99t understand sell sides view on $srpt. The past approvals were conditional on Phase 3 completion. Today\xe2\x80\x99s trial show\xe2\x80\xa6'
2021-01-08,b'RT @ej23ny: @JohnCendpts @Biotech2050 Lol $SRPT the first fool \xe2\x80\x9cRaymond James analyst Danielle Brill reiterated an Outperform rating and $2\xe2\x80\xa6'
2021-01-08,b'$SRPT $CMRX $MRUS $CLSD and more\n\nBiotech stocks on the move...\n\nhttps://t.co/RibRmo0gis'
